Co-Diagnostics (CODX) Tops Q2 EPS by $1.54, Beats on Revenue
Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of ($1.46), $1.54 better than the analyst estimate of ($3.00). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $132.58 thousand.
For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.
